Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Pharmaceuticals Regulatory News (HEMO)

Share Price Information for Hemogenyx Pharmaceuticals (HEMO)

Share Price is delayed by 15 minutes
Get Live Data
750.00    7.00 (0.93%)
Bid:
743.00
Ask:
779.00
Spread: 36.00 (4.845%)
Market Cap: £51.00m
HEMO Live PriceLast checked at - London Stock Exchange

Intraday Hemogenyx Pharmaceuticals Share Chart

Director/PDMR Shareholding

12 Feb 2018 07:00

RNS Number : 5133E
Hemogenyx Pharmaceuticals PLC
12 February 2018
 

Hemogenyx Pharmaceuticals Plc 

("Hemogenyx" or the "Company")

 

Director / PDMR Shareholding

 

Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow and blood stem cell transplantation, announces that it has been advised that on 9 February 2018 Adrian Beeston, Non-Executive Director, purchased 200,000 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at a price of 2.1p per share. Following this transaction Mr Beeston now has an interest in 6,331,969 Ordinary Shares, representing approximately 1.78 per cent. of the Company's issued share capital.

 

The Notification of Dealing Form provided in accordance with the requirements of MAR in relation to the transactions listed above are set out below:

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Adrian Beeston

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-executive Director

 

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Hemogenyx Pharmaceuticals Plc

b)

 

LEI

 

 

n/a

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of £0.01 each

Identification code

ISIN GB00BYX3WZ24

 

b)

 

Nature of the transaction

 

 

Purchase of Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

 

 

Price(s)

Volume(s)

 

 

2.1p

200,000

 

 

 

 

 

d)

 

Aggregated information

- Aggregated volume

 N/A - single transaction

- Price

e)

 

Date of the transaction

 

 

9 February 2018

f)

 

Place of the transaction

 

 

London Stock Exchange

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBIGDDDDGBGIC
Date   Source Headline
27th May 20222:05 pmRNSSecond Price Monitoring Extn
27th May 20222:00 pmRNSPrice Monitoring Extension
16th May 20227:00 amRNSImmuno-Oncology Summit Europe Presentation
29th Apr 20225:39 pmRNSFinal Results for the Year Ended 31 December 2021
21st Mar 20224:42 pmRNSSecond Price Monitoring Extn
21st Mar 20224:36 pmRNSPrice Monitoring Extension
21st Mar 20222:06 pmRNSSecond Price Monitoring Extn
21st Mar 20222:01 pmRNSPrice Monitoring Extension
16th Mar 20227:00 amRNSCBR Update
4th Mar 20222:05 pmRNSSecond Price Monitoring Extn
4th Mar 20222:00 pmRNSPrice Monitoring Extension
4th Mar 202211:05 amRNSSecond Price Monitoring Extn
4th Mar 202211:00 amRNSPrice Monitoring Extension
16th Feb 20227:00 amRNSHEMO-CAR-T pre-IND Meeting Request
12th Jan 20227:00 amRNSHemogenyx Pharmaceuticals Partnership with Selexis
5th Jan 20227:00 amRNSH.C. Wainwright Bioconnect Conference
22nd Dec 20212:05 pmRNSSecond Price Monitoring Extn
22nd Dec 20212:00 pmRNSPrice Monitoring Extension
22nd Dec 202111:06 amRNSSecond Price Monitoring Extn
22nd Dec 202111:01 amRNSPrice Monitoring Extension
20th Dec 20217:00 amRNSHemo-CAR-T partnership with WuXi ATU
13th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20218:55 amRNSHEMO-CAR-T pre-IND Meeting Request
24th Nov 20212:38 pmRNSConvertible Loans Repayment
18th Oct 20217:00 amRNSLease of New York Mink Building Custom Laboratory
13th Oct 20218:30 amRNSCDX Licence Agreement
12th Oct 20214:41 pmRNSSecond Price Monitoring Extn
12th Oct 20214:36 pmRNSPrice Monitoring Extension
30th Sep 20218:00 amRNSHalf-year Report
2nd Sep 20217:00 amRNSU.S. Approval of Monoclonal Antibody Patent
26th Jul 20217:00 amRNSAppointment of Business Advisor & Board Observer
2nd Jul 202111:23 amRNSCorporate Presentation
25th Jun 20213:32 pmRNSResult of Annual General Meeting
16th Jun 20214:40 pmRNSSecond Price Monitoring Extn
16th Jun 20214:35 pmRNSPrice Monitoring Extension
15th Jun 202112:41 pmRNSChanges to 2021 AGM Arrangements
15th Jun 202111:06 amRNSSecond Price Monitoring Extn
15th Jun 202111:00 amRNSPrice Monitoring Extension
2nd Jun 20214:11 pmRNSU.S. Approval and Issuance of CDX Antibody Patent
28th May 20212:00 pmRNSPosting of Annual Report & Notice of AGM
28th May 20218:52 amRNSTotal Voting Rights
27th May 202111:15 amRNSHolding(s) in Company
27th May 202111:15 amRNSHolding(s) in Company
26th May 20217:00 amRNSTermination of Mint Facility; Admission of Shares
19th May 20217:00 amRNSDirector/PDMR Shareholding
18th May 20219:05 amRNSSecond Price Monitoring Extn
18th May 20219:00 amRNSPrice Monitoring Extension
18th May 20217:00 amRNSLoan Notes Sale & Conversion; Facility Terminated
12th May 202112:00 pmRNSPublication of Supplementary Prospectus
12th May 202111:06 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.